BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Bicara Therapeutics (NASDAQ: BCAX) and maintained a price target of $39 for the stock. No additional financial figures or strategic changes were mentioned in the article.